The Correlation Study Between Serum S100?,PARK7 And Acute Ischemic Stroke

Background and ObjectiveIschemic stroke is a major subtype of all stroke with high incidence, morbidity and mortality, while, its etiology and pathogenesis is not very clear until now.With the aggravation of global aging problem, early diagnosis and treatment are of great significance. Currently, the iconographical diagnosis of cerebral apoplexy is mostly dependent on techniques like CT and MRI, which are expensive and clinically limited in application. Therefore, it is of enormous clinical significance to discover a more precise and viable serological marker for detecting cerebral apoplexy.The protein S100? is a acid calcium-binding protein with lower relative molecular weight, which mainly exists in neuroglial cells and neuronal cells of central nerve system and has an effect on neuron differentiation, axon growth and the calcium-signal regulation of intracellular transmission. Once the neurons damage, S100? releases into blood from cerebrospinal fluid by passing blood-brain barrier, resulting in the increasement of the concentration of blood S100?. The protein PARK7 is regarded as related gene of autosomal recessive inherited diseases in early-onset Parkinson's diseases, also called DJ-1, which plays an important role in molecular chaperone and anti-oxidative stress. Related researches displayed the close correlation that the dysfunction of PARK7 was responsible for stroke and neuro-degeneration. Our study aimed to detect the dynamic changes of S100? and PARK7 in acute ischemic stroke patients, to explore the effects on early diagnosis, clinical efficacy and the evaluation of prognosis. Materials and Methods 1 Clinical Data40 cases with acute ischemic stroke in our hospital and the People's Hospital of Henan province from January 2013 to January 2015 were selected as observation group(age range 35-81 years, 19 males and 21 females). The diagnosis criteria were as follows: conformance to the diagnosis of acute ischemic stroke certified by AHA/ASA; patients with first-onset and the disease time within 24 hours; diagnosis certified by CT or MRI examinations. And malignant tumors, brain trauma and severe organic pathologic injuries of different body systems were the main exclusion criteria. All patients were divided into mild-moderate group(NIHSS scores ?20 points) and severe group based on NIHSS scores(NIHSS scores >20 points). Simultaneously, we recruited 40 healthy volunteers as control group(age range 33-80 years, 18 males and 22 females). No significant differences were found between two groups regarding gender and age. 2 Experimental MethodsAt admission, at the third day and the seventh day, blood samples of 10 ml were collected in all study objects to detect the levels of homocysteine(HCY), C-reactive protein(CRP) and other related biochemical indices. We used immunochromatography method to measure the concentration of S100?. In addition, the level of PARK7 were examined by using enzyme-linked immunosorbent assay(ELISA) method. 3 Statistical AnalysisStatistical software SPSS19.0 was used in our study to analyze the collected data. ?2 test was applied to enumeration data. And continuous data according with normal distribution were represented by mean±standard deviation. Comparison between two groups was analyzed by t-test.Non-normal distribution is indicated by median(range interquartile) and the comparison between groups are inspected with t'. multi-group comparisons by F-test. We adopted linear-regression model to discuss the correlation analysis and used receiver operating characteristic(ROS) curve to assess the sensitivity and the specificity of the detected indicators. Results1. After the patient was hospitalized within 24 hours, on the 3rd and 7th day, the tested concentrations of serum S100? in mild and medium observation group are respectively 0.75(0.64-0.84), 1.05(0.84-1.18) and 0.54(0.47-0.63), concentrations of serum PARK7 are 25.30(22.37-26.33), 22.31(19.98-23.15) and 20.68(18.17-21.21);counterparts concentrations in severe observation group are 1.83(1.75-1.95), 2.25(2.12-2.50) and 1.39(1.22-1.54), and in serum PARK7 are 35.07(32.87-38.13), 31.56(28.75-34.99) and 28.57(25.96-31.09). The difference we found in these two groups are of statistical significance(P<0.01). The concentration of serum S100?in control group is 0.27(0.17-0.40) and that of serum PARK7 is 14.04(12.34-16.29). The difference we discovered in our results showed prominent statistic significance(P<0.0001).2. With the application of ROC curve, the critical value of S100? regarded as 0.5000ug/L, IS was diagnosed by S100? with the sensitivity of 90% and the specificity of 92.5%(AUC=0.985, P=0.000); Similarly, the marginal value of PARK7 considered as 20.6850ug/L, the sensitivity of 95% and the specificity of 97.5% were identified for the diagnosis of IS(AUC=0.998, P=0.000); Simultaneously, based on the above-mentioned values, the combination of S100? and PARK7 disclosed higher and more stable diagnostic value(95%, 97.5% respectively)(AUC=0.998, P=0.000).3. The collected data indicated that the more the NIHSS scores, namely the severer the neurologic impairment, the levels of S100? and PARK7 were higher. Likewise, the severe group showed significant differences relative to the mild-moderate group. Furthermore, the correlation analysis revealed that the NIHSS scores were closely positive related to levels of S100? and PARK7(P<0.0001). Conclusions1. Patients with acute ischemic stroke have higher levels of S100? and PARK7, S100? begins to rise in the incidence within 24 h, peaked at day 3, day 7 decreased. But PARK7 onset 24 hours and reached the peak level gradually decreased.2. Levels of S100? and PARK7 have an effect on the diagnosis of IS with high sensitivity and high specificity.3. NIHSS scores have positive correlations with the levels of S100? and PARK7, thus we can monitor diseases and evaluate prognosis via indices detection.